Literature DB >> 22872227

An orthotopic bladder tumor model and the evaluation of intravesical saRNA treatment.

Moo Rim Kang1, Glen Yang, Klaus Charisse, Hila Epstein-Barash, Muthiah Manoharan, Long-Cheng Li.   

Abstract

We present a novel method for treating bladder cancer with intravesically delivered small activating RNA (saRNA) in an orthotopic xenograft mouse bladder tumor model. The mouse model is established by urethral catheterization under inhaled general anesthetic. Chemical burn is then introduced to the bladder mucosa using intravesical silver nitrate solution to disrupt the bladder glycosaminoglycan layer and allows cells to attach. Following several washes with sterile water, human bladder cancer KU-7-luc2-GFP cells are instilled through the catheter into the bladder to dwell for 2 hours. Subsequent growth of bladder tumors is confirmed and monitored by in vivo bladder ultrasound and bioluminescent imaging. The tumors are then treated intravesically with saRNA formulated in lipid nanoparticles (LNPs). Tumor growth is monitored with ultrasound and bioluminescence. All steps of this procedure are demonstrated in the accompanying video.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22872227      PMCID: PMC3476411          DOI: 10.3791/4207

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  8 in total

1.  Preliminary results of myoblast injection into the urethra and bladder wall: a possible method for the treatment of stress urinary incontinence and impaired detrusor contractility.

Authors:  M B Chancellor; T Yokoyama; S Tirney; C E Mattes; H Ozawa; N Yoshimura; W C de Groat; J Huard
Journal:  Neurourol Urodyn       Date:  2000       Impact factor: 2.696

2.  An orthotopic model of murine bladder cancer.

Authors:  Georgina L Dobek; W T Godbey
Journal:  J Vis Exp       Date:  2011-02-06       Impact factor: 1.355

3.  Mouse bladder wall injection.

Authors:  Chi-Ling Fu; Charity A Apelo; Baldemar Torres; Kim H Thai; Michael H Hsieh
Journal:  J Vis Exp       Date:  2011-07-12       Impact factor: 1.355

4.  Small dsRNAs induce transcriptional activation in human cells.

Authors:  Long-Cheng Li; Steven T Okino; Hong Zhao; Deepa Pookot; Robert F Place; Shinji Urakami; Hideki Enokida; Rajvir Dahiya
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-03       Impact factor: 11.205

5.  Rational design of cationic lipids for siRNA delivery.

Authors:  Sean C Semple; Akin Akinc; Jianxin Chen; Ammen P Sandhu; Barbara L Mui; Connie K Cho; Dinah W Y Sah; Derrick Stebbing; Erin J Crosley; Ed Yaworski; Ismail M Hafez; J Robert Dorkin; June Qin; Kieu Lam; Kallanthottathil G Rajeev; Kim F Wong; Lloyd B Jeffs; Lubomir Nechev; Merete L Eisenhardt; Muthusamy Jayaraman; Mikameh Kazem; Martin A Maier; Masuna Srinivasulu; Michael J Weinstein; Qingmin Chen; Rene Alvarez; Scott A Barros; Soma De; Sandra K Klimuk; Todd Borland; Verbena Kosovrasti; William L Cantley; Ying K Tam; Muthiah Manoharan; Marco A Ciufolini; Mark A Tracy; Antonin de Fougerolles; Ian MacLachlan; Pieter R Cullis; Thomas D Madden; Michael J Hope
Journal:  Nat Biotechnol       Date:  2010-01-17       Impact factor: 54.908

6.  Antitumor effect of dsRNA-induced p21(WAF1/CIP1) gene activation in human bladder cancer cells.

Authors:  Zhong Chen; Robert F Place; Zhe-Jun Jia; Deepa Pookot; Rajvir Dahiya; Long-Cheng Li
Journal:  Mol Cancer Ther       Date:  2008-03       Impact factor: 6.261

7.  A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging.

Authors:  Boris A Hadaschik; Peter C Black; Jason C Sea; Adam R Metwalli; Ladan Fazli; Colin P Dinney; Martin E Gleave; Alan I So
Journal:  BJU Int       Date:  2007-09-10       Impact factor: 5.588

8.  Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice.

Authors:  C P Dinney; R Fishbeck; R K Singh; B Eve; S Pathak; N Brown; B Xie; D Fan; C D Bucana; I J Fidler
Journal:  J Urol       Date:  1995-10       Impact factor: 7.450

  8 in total
  7 in total

1.  Development of a murine intravesical orthotopic human bladder cancer (mio-hBC) model.

Authors:  Peter A Raven; Ninadh M D'Costa; Igor Moskalev; Zheng Tan; Sebastian Frees; Claudia Chavez-Munoz; Alan I So
Journal:  Am J Clin Exp Urol       Date:  2018-12-20

2.  P70S6K and Elf4E dual inhibition is essential to control bladder tumor growth and progression in orthotopic mouse non-muscle invasive bladder tumor model.

Authors:  Byung Hoon Chi; Soon-Ja Kim; Ho Kyung Seo; Hye-Hyun Seo; Sang-Jin Lee; Jong Kyou Kwon; Tae-Jin Lee; In Ho Chang
Journal:  J Korean Med Sci       Date:  2015-02-16       Impact factor: 2.153

3.  Minimally invasive establishment of murine orthotopic bladder xenografts.

Authors:  Wolfgang Jäger; Igor Moskalev; Claudia Janssen; Tetsutaro Hayashi; Killian M Gust; Shannon Awrey; Peter C Black
Journal:  J Vis Exp       Date:  2014-02-11       Impact factor: 1.355

4.  In vivo biodistribution and toxicity of intravesical administration of quantum dots for optical molecular imaging of bladder cancer.

Authors:  Ying Pan; Timothy Chang; Gautier Marcq; Changhao Liu; Bernhard Kiss; Robert Rouse; Kathleen E Mach; Zhen Cheng; Joseph C Liao
Journal:  Sci Rep       Date:  2017-08-24       Impact factor: 4.379

5.  Specific up-regulation of p21 by a small active RNA sequence suppresses human colorectal cancer growth.

Authors:  Lu-Lu Wang; Hui-Hui Guo; Yun Zhan; Chen-Lin Feng; Shuai Huang; Yan-Xing Han; Wen-Sheng Zheng; Jian-Dong Jiang
Journal:  Oncotarget       Date:  2017-04-11

6.  Differential Regulation of Vascular Endothelial Growth Factors by Promoter-targeted shRNAs.

Authors:  Nihay Laham-Karam; Marianne Lalli; Nastasia Leinonen; Seppo Ylä-Herttuala
Journal:  Mol Ther Nucleic Acids       Date:  2015-05-19       Impact factor: 10.183

7.  Preclinical pharmacodynamic evaluation of antibiotic nitroxoline for anticancer drug repurposing.

Authors:  Q I Zhang; Shanshan Wang; Dexuan Yang; Kevin Pan; Linna Li; Shoujun Yuan
Journal:  Oncol Lett       Date:  2016-03-29       Impact factor: 2.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.